The Janssen Pharmaceutical Companies of Johnson & Johnson has decided to withdraw the phase three LOTUS study of STELARA (ustekinumab) in Systemic Lupus Erythematosus (SLE), it was reported on Friday.
The company has taken this step because of the lack of efficacy in SLE.
Interim safety findings for Stelara were consistent with the product's known safety profile and no new safety signals were found.
Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyse the totality of the study data and publish findings. The company stated that the decision to discontinue the LOTUS study does not impact any other ongoing studies with ustekinumab or current indications.
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes